Corbus Pharmaceuticals Holdings, Inc.
www.corbuspharma.comAI Executive Summary
AI-powered analysis of 10-Q filing content
Corbus Pharmaceuticals shows significant financial deterioration with 35% increase in net losses to $23M, 27% rise in R&D spending to $19.8M, and concerning cash burn patterns. The company's substantial accumulated deficit of $578M and declining total assets signal potential liquidity challenges ahead.
Red Flags Detected (6)
Net loss increased 35% to $22.97M vs $16.98M prior year
Total assets declined 14% from $168M to $144M in just 3 months
Cash and investments decreased $25M in Q1 alone ($163M to $138M)
3 more red flags detected
Key Takeaways
Company burned through $25M in cash/investments in single quarter
R&D spending acceleration suggests active clinical programs but increases financial pressure
2 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.